{
    "root": "406a07e3-a3f8-4fef-901e-021d00743c40",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Remifentanil Hydrochloride"
    },
    "value": "20250213",
    "ingredients": [
        {
            "name": "REMIFENTANIL HYDROCHLORIDE",
            "code": "5V444H5WIC"
        },
        {
            "name": "GLYCINE",
            "code": "TE7660XO1C"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        }
    ],
    "indications": "remifentanil hydrochloride ( hcl ) injection indicated intravenous ( iv ) : \u2022as analgesic agent induction maintenance general anesthesia inpatient outpatient procedures . \u2022for continuation analgesic immediate postoperative period adult patients direct supervision anesthesia practitioner postoperative anesthesia care unit intensive care setting . \u2022as analgesic component monitored anesthesia care adult patients .",
    "contraindications": "\u2022 monitor patients closely respiratory depression initiating therapy following increases adjust accordingly . ( 2.1 ) \u2022 initial adults : full prescribing information recommended doses adult patients . ( 2.2 , 2.3 ) \u2022 initial pediatric patients : full prescribing information recommended doses pediatric patients . ( 2.2 ) \u2022 geriatric patients : starting doses decreased 50 % elderly patients ( > 65 years ) . ( 2.6 )",
    "warningsAndPrecautions": "remifentanil hcl injection stored 2\u00b0 25\u00b0c ( 36\u00b0 77\u00b0f ) . remifentanil hcl iv supplied follows : product code unit sale strength prx723103 ndc 63323-723-06 unit 10 1 mg per vial ndc 63323-723-043 ml single dose vial discard unused portion . container closure made natural rubber latex . brand names mentioned document trademarks respective owners . premierprorx\u00ae registered trademark premier healthcare alliance , l.p. , used license . manufactured : fresenius kabi lake zurich , il 60047 www.fresenius-kabi.com/us 451651a",
    "adverseReactions": "remifentanil hcl contraindicated : \u2022for epidural intrathecal due presence glycine formulation [ nonclinical toxicology ( 13 ) ] . \u2022in patients hypersensitivity remifentanil ( e.g . , anaphylaxis ) [ ( 6.2 ) ] .",
    "indications_original": "Remifentanil hydrochloride (HCl) for injection is indicated for intravenous (IV) administration:\n                  \n                     \n                        \u2022As an analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures.\n                     \n                        \u2022For continuation as an analgesic into the immediate postoperative period in adult patients under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting.\n                     \n                        \u2022As an analgesic component of monitored anesthesia care in adult patients.",
    "contraindications_original": "\u2022 Monitor patients closely for respiratory depression when initiating therapy and following dosage increases and adjust the dosage accordingly. ( 2.1 ) \u2022 Initial Dosage in Adults : See full prescribing information for recommended doses in adult patients. ( 2.2 , 2.3 ) \u2022 Initial Dosage in Pediatric Patients : See full prescribing information for recommended doses in pediatric patients. ( 2.2 ) \u2022 Geriatric Patients : The starting doses should be decreased by 50% in elderly patients (> 65 years). ( 2.6 )",
    "warningsAndPrecautions_original": "Remifentanil HCl for injection should be stored at 2\u00b0 to 25\u00b0C (36\u00b0 to 77\u00b0F). Remifentanil HCl for IV use is supplied as follows:\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Product Code\n                              \n                           \n                           \n                              \n                                 Unit of Sale\n                              \n                           \n                           \n                              \n                                 Strength\n                              \n                           \n                           \n                              \n                                 Each\n                              \n                           \n                        \n                        \n                           \n                              PRX723103\n                           \n                           \n                              NDC 63323-723-06 Unit of 10\n                           \n                           \n                              1 mg per vial\n                           \n                           \n                              NDC 63323-723-043 mL Single Dose Vial\n                           \n                        \n                     \n                  \n                  Discard unused portion.\n                  The container closure is not made with natural rubber latex.\n                  The brand names mentioned in this document are the trademarks of their respective owners.\n                  \n                      PREMIERProRx\u00ae is a registered trademark of Premier Healthcare Alliance, L.P., used under license.\n                  Manufactured by:\n                     Fresenius Kabi\n                  \n                  Lake Zurich, IL 60047\n                  www.fresenius-kabi.com/us\n                  451651A",
    "adverseReactions_original": "Remifentanil HCl is contraindicated:\n                  \n                     \n                        \u2022For epidural or intrathecal administration due to the presence of glycine in the formulation [see Nonclinical Toxicology (13)].\n                     \n                        \u2022In patients with hypersensitivity to remifentanil (e.g., anaphylaxis) [see Adverse Reactions (6.2)]."
}